These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24911527)

  • 1. Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
    De Schutter JW; Park J; Leung CY; Gormley P; Lin YS; Hu Z; Berghuis AM; Poirier J; Tsantrizos YS
    J Med Chem; 2014 Jul; 57(13):5764-76. PubMed ID: 24911527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
    Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
    J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase.
    Park J; Leung CY; Matralis AN; Lacbay CM; Tsakos M; Fernandez De Troconiz G; Berghuis AM; Tsantrizos YS
    J Med Chem; 2017 Mar; 60(5):2119-2134. PubMed ID: 28208018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
    Gritzalis D; Park J; Chiu W; Cho H; Lin YS; De Schutter JW; Lacbay CM; Zielinski M; Berghuis AM; Tsantrizos YS
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1117-23. PubMed ID: 25630225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
    De Schutter JW; Shaw J; Lin YS; Tsantrizos YS
    Bioorg Med Chem; 2012 Sep; 20(18):5583-91. PubMed ID: 22884353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
    Lin YS; Park J; De Schutter JW; Huang XF; Berghuis AM; Sebag M; Tsantrizos YS
    J Med Chem; 2012 Apr; 55(7):3201-15. PubMed ID: 22390415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates.
    El-Sayed NF; El-Hussieny M; Mansour ST; Fouad MA; Saad MA; Ewies EF
    Eur J Med Chem; 2024 Oct; 276():116679. PubMed ID: 39018923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase--parallel synthesis of analogs via a trimethylsilyl ylidene intermediate.
    Leung CY; Langille AM; Mancuso J; Tsantrizos YS
    Bioorg Med Chem; 2013 Apr; 21(8):2229-2240. PubMed ID: 23477945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR Models for Nitrogen Containing Monophosphonate and Bisphosphonate Derivatives as Human Farnesyl Pyrophosphate Synthase Inhibitors Based on Monte Carlo Method.
    Kumar P; Kumar A; Sindhu J; Lal S
    Drug Res (Stuttg); 2019 Mar; 69(3):159-167. PubMed ID: 30036888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate.
    Park J; Lin YS; Tsantrizos YS; Berghuis AM
    Acta Crystallogr F Struct Biol Commun; 2014 Mar; 70(Pt 3):299-304. PubMed ID: 24598914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.
    Jahnke W; Rondeau JM; Cotesta S; Marzinzik A; Pellé X; Geiser M; Strauss A; Götte M; Bitsch F; Hemmig R; Henry C; Lehmann S; Glickman JF; Roddy TP; Stout SJ; Green JR
    Nat Chem Biol; 2010 Sep; 6(9):660-6. PubMed ID: 20711197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.
    Fernández D; Ortega-Castro J; Mariño L; Perelló J; Frau J
    J Comput Aided Mol Des; 2015 Jul; 29(7):667-80. PubMed ID: 26081258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding.
    Marzinzik AL; Amstutz R; Bold G; Bourgier E; Cotesta S; Glickman JF; Götte M; Henry C; Lehmann S; Hartwieg JC; Ofner S; Pellé X; Roddy TP; Rondeau JM; Stauffer F; Stout SJ; Widmer A; Zimmermann J; Zoller T; Jahnke W
    ChemMedChem; 2015 Nov; 10(11):1884-91. PubMed ID: 26381451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoprenoids and tau pathology in sporadic Alzheimer's disease.
    Pelleieux S; Picard C; Lamarre-Théroux L; Dea D; Leduc V; Tsantrizos YS; Poirier J
    Neurobiol Aging; 2018 May; 65():132-139. PubMed ID: 29476987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase.
    Rodriguez JB; Falcone BN; Szajnman SH
    Expert Opin Drug Discov; 2016; 11(3):307-20. PubMed ID: 26781029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
    Wiemer AJ; Tong H; Swanson KM; Hohl RJ
    Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
    Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
    Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.
    Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D
    Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase.
    Park J; Rodionov D; De Schutter JW; Lin YS; Tsantrizos YS; Berghuis AM
    PLoS One; 2017; 12(10):e0186447. PubMed ID: 29036218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
    Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
    BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.